U.S. FDA approves Alexion Pharma’s blood disorder drug

ByNews Videos

Dec 21, 2018 #ALEXION, #Biotechnology and Medical Research (TRBC), #Content produced in Bangalore, #Drug and Device Development, #FDA, #Haematology / Blood Disorders, #Healthcare (TRBC), #Pharmaceuticals (TRBC), #Pharmaceuticals and Medical Research (TRBC), #PHARMS, #united states, #US

[ad_1]

(Reuters) – The U.S. Food and Drug Administration has approved Alexion Pharmaceuticals Inc’s blood disorder drug Ultomiris, the pharma regulator’s website showed on Friday.

The drug aims to treat paroxysmal nocturnal hemoglobinuria (PNH), a rare, acquired, life-threatening disorder in which red blood cells divide prematurely.

Reporting by Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila

Our Standards:The Thomson Reuters Trust Principles.

[ad_2]

Source link